From: Belisle, Caryn Domenici To: Subject: BOP: 247 CMR 5.00, 6.00, 9.00, 12.00, 15.00 & 20.00 Date: Thursday, July 13, 2017 1:58:52 PM High Importance: Dear Madam/Sir: I am requesting your strong consideration of the comments raised by MHA and MSHP in comment letter submitted to the Department of Public Health and the Board of Registration in Pharmacy, regarding edits to 247 CMR 6, 247 CMR 9, and 247 CMR 20. While we support the efforts by the Board to develop meaningful regulations that adopt the principals of the 2014 Compounding Pharmacy Reform law, there are several operational and scope of practice clarifications that are necessary in the Board’s proposed regulations to reduce unnecessary administrative requirements to ensure continued patient care and quality standards are being met. I appreciate your consideration of the comments submitted. Sincerely, Caryn Belisle Caryn D. Belisle, RPh, MBA Director of Pharmacy Regulatory Compliance, Quality, and Safety Brigham and Women's Hospital Boston, MA Office: Mobile: 617-842-0868 The information in this e-mail is intended only for the person to whom it is addressed. If you believe this e-mail was sent to you in and the e-mail contains patient information, please contact the Partners Compliance HelpLine at . If the e-mail was sent to you in error but does not contain patient information, please contact the sender and properly dispose of the e-mail.
From: Belisle, Caryn Domenici To: Subject: BOP: 247 CMR 5.00, 6.00, 9.00, 12.00, 15.00 & 20.00 Date: Thursday, July 13, 2017 1:58:52 PM Importance: High Dear Madam/Sir: I am requesting your strong consideration of the comments raised by MHA and MSHP in comment letter submitted to the Department of Public Health and the Board of Registration in Pharmacy, regarding edits to 247 CMR 6, 247 CMR 9, and 247 CMR 20. While we support the efforts by the Board to develop meaningful regulations that adopt the principals of the 2014 Compounding Pharmacy Reform law, there are several operational and scope of practice clarifications that are necessary in the Board’s proposed regulations to reduce unnecessary administrative requirements to ensure continued patient care and quality standards are being met. I appreciate your consideration of the comments submitted. Sincerely, Caryn Belisle Caryn D. Belisle, RPh, MBA Director of Pharmacy Regulatory Compliance, Quality, and Safety Brigham and Women's Hospital Boston, MA Office: Mobile: 617-842-0868 The information in this e-mail is intended only for the person to whom it is addressed. If you believe this e-mail was sent to you in and the e-mail contains patient information, please contact the Partners Compliance HelpLine at . If the e-mail was sent to you in error but does not contain patient information, please contact the sender and properly dispose of the e-mail.
belisle-247cmr.docx